- Home
- GDL vs KPTI Comparison
GDL vs KPTI Comparison
Compare GDL & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDL
- KPTI
- Stock Information
- Founded
- GDL 2006
- KPTI 2008
- Country
- GDL United States
- KPTI United States
- Employees
- GDL N/A
- KPTI N/A
- Industry
- GDL Investment Managers
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- GDL Finance
- KPTI Health Care
- Exchange
- GDL Nasdaq
- KPTI Nasdaq
- Market Cap
- GDL 94.9M
- KPTI 90.7M
- IPO Year
- GDL N/A
- KPTI 2013
- Fundamental
- Price
- GDL $8.15
- KPTI $0.66
- Analyst Decision
- GDL
- KPTI Strong Buy
- Analyst Count
- GDL 0
- KPTI 4
- Target Price
- GDL N/A
- KPTI $5.00
- AVG Volume (30 Days)
- GDL 11.2K
- KPTI 1.0M
- Earning Date
- GDL 01-01-0001
- KPTI 02-27-2025
- Dividend Yield
- GDL 6.02%
- KPTI N/A
- EPS Growth
- GDL N/A
- KPTI N/A
- EPS
- GDL N/A
- KPTI N/A
- Revenue
- GDL N/A
- KPTI $148,442,000.00
- Revenue This Year
- GDL N/A
- KPTI $6.67
- Revenue Next Year
- GDL N/A
- KPTI $8.58
- P/E Ratio
- GDL N/A
- KPTI N/A
- Revenue Growth
- GDL N/A
- KPTI 1.77
- 52 Week Low
- GDL $7.65
- KPTI $0.58
- 52 Week High
- GDL $8.13
- KPTI $1.95
- Technical
- Relative Strength Index (RSI)
- GDL 59.30
- KPTI 44.20
- Support Level
- GDL $8.12
- KPTI $0.61
- Resistance Level
- GDL $8.17
- KPTI $0.73
- Average True Range (ATR)
- GDL 0.06
- KPTI 0.08
- MACD
- GDL 0.01
- KPTI -0.00
- Stochastic Oscillator
- GDL 89.47
- KPTI 26.13
About GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.